DK1802650T3 - 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion - Google Patents

3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion

Info

Publication number
DK1802650T3
DK1802650T3 DK05815625.8T DK05815625T DK1802650T3 DK 1802650 T3 DK1802650 T3 DK 1802650T3 DK 05815625 T DK05815625 T DK 05815625T DK 1802650 T3 DK1802650 T3 DK 1802650T3
Authority
DK
Denmark
Prior art keywords
hepatitis
treatment
thioether
infection
prevention
Prior art date
Application number
DK05815625.8T
Other languages
Danish (da)
English (en)
Inventor
Hans Georg Fliri
David Renwick Houck
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Application granted granted Critical
Publication of DK1802650T3 publication Critical patent/DK1802650T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK05815625.8T 2004-10-01 2005-09-30 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion DK1802650T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61515204P 2004-10-01 2004-10-01
US70762605P 2005-08-11 2005-08-11
PCT/US2005/035533 WO2006039668A2 (en) 2004-10-01 2005-09-30 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection

Publications (1)

Publication Number Publication Date
DK1802650T3 true DK1802650T3 (da) 2012-02-06

Family

ID=36143148

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05815625.8T DK1802650T3 (da) 2004-10-01 2005-09-30 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion

Country Status (19)

Country Link
US (2) US20100167996A1 (enExample)
EP (1) EP1802650B1 (enExample)
JP (2) JP5139065B2 (enExample)
KR (1) KR101309409B1 (enExample)
CN (1) CN101773661B (enExample)
AT (1) ATE530561T1 (enExample)
AU (1) AU2005292162B2 (enExample)
BR (1) BRPI0516737A (enExample)
CA (1) CA2583494C (enExample)
DK (1) DK1802650T3 (enExample)
ES (1) ES2373450T3 (enExample)
IL (1) IL182315A (enExample)
MX (1) MX2007003538A (enExample)
NZ (1) NZ554514A (enExample)
PL (1) PL1802650T3 (enExample)
PT (1) PT1802650E (enExample)
RU (1) RU2399628C2 (enExample)
SI (1) SI1802650T1 (enExample)
WO (1) WO2006039668A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
BRPI0616476A2 (pt) * 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
CA2623898C (en) 2005-10-26 2013-12-24 Astellas Pharma Inc. New cyclic peptide compounds
CA2643680A1 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors and their uses
ATE502633T1 (de) * 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
EP2027761A1 (fr) * 2006-06-02 2009-02-25 Claude Annie Perrichon Gestion des electrons actifs
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
ES2396170T3 (es) 2007-05-02 2013-02-19 Astellas Pharma Inc. Nuevos compuestos péptídicos ciclicos
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
BRPI0911709A2 (pt) 2008-07-30 2017-06-20 Isotechnika Labs Inc composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
WO2010080874A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
SG173180A1 (en) 2009-01-30 2011-09-29 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
US20110144005A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
BR112012014729A2 (pt) * 2009-12-18 2016-03-29 Boehringer Ingelheim Int terapia combinada contra hcv
AU2010339460A1 (en) 2009-12-30 2012-07-19 Scynexis Inc. Cyclosporine analogues
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012009715A2 (en) 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012021796A2 (en) 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
EP2624826B1 (en) 2010-10-08 2018-07-18 Novartis AG Vitamin e formulations of sulfamide ns3 inhibitors
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JP6093307B2 (ja) * 2010-12-03 2017-03-08 エス アンド ティー グローバル インク． ウイルス感染の治療および予防のための新規シクロスポリン誘導体
JP6144627B2 (ja) 2010-12-15 2017-06-07 コントラヴィア ファーマシューティカルズ、インク． アミノ酸１および３で修飾されたシクロスポリン類似体分子
RU2448690C1 (ru) * 2011-03-15 2012-04-27 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма пролонгированного действия нестероидного противовоспалительного средства кетопрофен, способ получения
WO2013028615A2 (en) * 2011-08-19 2013-02-28 S&T Golbal Inc. Novel cyclosporin derivatives for the treatment and prevention of viral infections
EP2855508B1 (en) 2012-06-01 2018-02-14 Allergan, Inc. Cyclosporin a analogs
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
SG11201601274QA (en) * 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
US10077289B2 (en) 2015-03-31 2018-09-18 Allergan, Inc. Cyclosporins modified on the MeBmt sidechain by heterocyclic rings
WO2017004304A1 (en) * 2015-06-30 2017-01-05 Cypralis Limited Novel macrocycles
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
AU2020363688A1 (en) 2019-10-12 2022-04-21 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
IL296586B1 (en) * 2020-03-26 2026-04-01 Farsight Medical Tech Shanghai Co Ltd Cyclophilin inhibitors and their uses
CN113694177B (zh) * 2020-04-15 2022-06-17 睿诺医疗科技（上海）有限公司 器官损伤的预防和治疗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4885276A (en) * 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
ATE148469T1 (de) * 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5863550A (en) * 1993-03-31 1999-01-26 Tokyo Tanabe Company Limited Cholestasis ameliorant
CA2167537A1 (en) * 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
US5739105A (en) * 1994-06-01 1998-04-14 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
PL324531A1 (en) * 1995-07-17 1998-06-08 Chem Ag C Derivatives of cyclosporin effective against hiv virus
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2212583T3 (es) * 1998-06-12 2004-07-16 C-Chem Ag Nuevas ciclosporinas.
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
PT1091975E (pt) * 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6521595B1 (en) * 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
BRPI0616476A2 (pt) * 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en) * 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
ATE502633T1 (de) * 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
US7576057B2 (en) * 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US9090671B2 (en) * 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
WO2010080874A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2010080878A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Combination of a cyclosporine derivative and nucleosides for treating hcv
US20110144005A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides

Also Published As

Publication number Publication date
IL182315A0 (en) 2007-07-24
US20100167996A1 (en) 2010-07-01
PT1802650E (pt) 2011-12-30
MX2007003538A (es) 2008-01-16
AU2005292162B2 (en) 2011-11-10
RU2399628C2 (ru) 2010-09-20
ES2373450T3 (es) 2012-02-03
EP1802650A2 (en) 2007-07-04
EP1802650A4 (en) 2008-08-20
KR20070073841A (ko) 2007-07-10
SI1802650T1 (sl) 2012-03-30
WO2006039668A2 (en) 2006-04-13
JP2008514732A (ja) 2008-05-08
CN101773661B (zh) 2013-09-25
WO2006039668A3 (en) 2007-04-19
US20120264679A1 (en) 2012-10-18
BRPI0516737A (pt) 2008-04-29
PL1802650T3 (pl) 2012-04-30
WO2006039668B1 (en) 2007-05-31
ATE530561T1 (de) 2011-11-15
JP2012167113A (ja) 2012-09-06
CN101773661A (zh) 2010-07-14
CA2583494A1 (en) 2006-04-13
HK1108703A1 (en) 2008-05-16
JP5139065B2 (ja) 2013-02-06
EP1802650B1 (en) 2011-10-26
IL182315A (en) 2013-08-29
CA2583494C (en) 2014-01-21
NZ554514A (en) 2010-10-29
KR101309409B1 (ko) 2013-09-23
AU2005292162A1 (en) 2006-04-13
RU2007116119A (ru) 2008-11-10

Similar Documents

Publication Publication Date Title
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
NO20091704L (no) Inhibitorer av hepatitt C virus
NO20091706L (no) Inhibitorer av hepatitt C virus
NO20091707L (no) Inhibitorer av hepatitt C virus
EA200900297A1 (ru) Ингибиторы вируса гепатита с
ATE498630T1 (de) Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
EA200900298A1 (ru) Ингибиторы вируса гепатита с
CY1109671T1 (el) Αναστολεις της πρωτεασης ns3 του hcv
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
ATE526341T1 (de) Makrozyklische verbindungen als antivirale mittel
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2007008657A3 (en) Hepatitis c virus inhibitors
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
NO20073105L (no) Pyridazinonforbindelser
IS7533A (is) Lifrarbólgu C-veirutálmar
WO2008051477A3 (en) Hcv ns3 protease inhibitors
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
EA201000277A1 (ru) Соединения для лечения гепатита с
NO20074167L (no) Peptidiske forbindelser
UA95990C2 (en) Hcv ns3 protease inhibitors
ATE474553T1 (de) Neue pulverinhalativa auf basis modifizierter laktosemischungen als hilfsstoff